PITTSBURGH, PA – July 13, 2026 — Groundbreaking work by a Pittsburgh-based researcher that has already had global impact for children with Cortical Visual Impairment (CVI) has received new recognition in the official journal of the American Academy of Ophthalmology .
CVI is a brain-based visual disorder that is the leading cause of pediatric visual impairment in developed countries. Unfortunately, due to low awareness, CVI is often misdiagnosed as other conditions—such as autism, ADHD, or a learning disability. This leads to costly, ineffective interventions and challenging, deep impacts on families struggling to find solutions for their child. S ome estimates suggest that at least 3% of primary school children globally exhibit CVI-related visual problems.
Christine Roman-Lantzy, Ph.D., founder and director of Pediatric VIEW at The Children’s Home of Pittsburgh , developed The CVI Range Assessment over decades of clinical work and research. Now, a new peer-reviewed study published in Ophthalmology Science has confirmed that The CVI Range Assessment is a valid and reliable instrument for evaluating functional vision in children with CVI.
The findings provide the first rigorous clinical validation of a tool that has been used by educators and vision specialists for decades, supplying the strongest evidence to date that The CVI Range Assessment meets clinical and psychometric standards. The study represents a meaningful shift in how CVI can be identified and addressed within the medical community.
“All too often, families anguish over a diagnosis of autism or attention disorder that the family intrinsically feels falls short of the needs of their child. Unfortunately, many diagnosticians are unfamiliar with the signs of CVI, and as a result, may inadvertently misdiagnose a child with CVI as having a different condition,” explained Christine Roman-Lantzy, PhD . “Incorrect diagnosis clearly results in the child receiving ineffective intervention, potentially for the span of their school life. Early detection of CVI is critical, and medical screenings continue to skip over a few key questions that could unlock the pathway to discover CVI earlier in a child’s development. The challenge continues to be a lack of awareness about this disorder in the broader medical community.”
“The validation from this study gives clinicians worldwide a reliable way to identify and measure a child’s vision. This is critical to design the most accurate supports that facilitate learning, social opportunities, and self-determination,” continued Dr. Roman-Lantzy . “The use of The CVI Range can also reliably be used to measure the changes in functional vision over time. The clinical vetting The CVI Range delivers represents progress for an entire field—but more importantly, it brings hope for the millions of families and teachers who struggle with the complexities of getting a clear diagnosis of CVI for a child, so we can start to address it.”
The prospective longitudinal study enrolled 40 children with CVI, assessing them at baseline and one year later using The CVI Range for Clinical Research (CVI Range-CR) — Dr. Roman-Lantzy’s assessment applied for clinical research settings. The results were clear across every metric tested: internal consistency, intra-rater reliability, correlation to clinical measures of visual behavior, and sensitivity to detect meaningful change over time. Authors concluded that The CVI Range-CR is a reliable and valid measure of functional vision in children with CVI — and that it is sensitive enough to detect real change, making it fit for use in clinical trials.
CVI is the leading cause of childhood visual impairment in developed countries. Unlike ocular conditions, CVI involves dysfunction in the brain’s visual processing centers — meaning standard eye exams frequently miss or underestimate the impairment. The CVI Range measures how a child uses vision in daily life guided by 10 distinct visual and behavioral characteristics, filling a critical diagnostic gap.
Until now, The CVI Range has been used primarily in educational settings, where it has guided individualized interventions for children at schools and in therapy. Its clinical validation changes the equation: it gives physicians, researchers, and health systems a standardized, evidence-based tool for earlier and more accurate diagnosis, and for measuring treatment outcomes in future trials.
"For nearly a decade, I have been referring patients to Teachers for the Visually Impaired, who all use Dr. Roman-Lantzy’s CVI Range Assessment and practice modalities,” said Dr. Edward Kuwera , an ophthalmologist who was not affiliated with this study and is based at Johns Hopkins School of Medicine, where he specializes in pediatric conditions and adult strabismus. “These resources have had a tremendous impact on my understanding and ability to provide optimal care to my patients diagnosed with CVI, and helped me to differentiate their behavior from autism – conditions requiring very different forms of therapy. The profound impact Dr. Roman-Lantzy has had on my patients’ outcomes and quality of life cannot be overstated, as her work is truly indispensable in pediatric ophthalmology.”
“Vision shapes all areas of development,” said Sarah W. Blackstone, Ph.D., CCC-SLP , a prominent researcher not affiliated with this study, but with extensive experience developing educational and communication strategies for children with CVI – including serving as a member of the Board of Directors for The Bridge School , which uses an internationally recognized model of inclusive education and communication access for children with speech and physical disabilities. “Under Dr. Roman-Lantzy's guidance, longitudinal research at The Bridge School in California showed that all students with CVI improved in their use of vision (measured by The CVI Range over multiple years). Improvement in vision strongly correlated with improvements across other developmental areas. In short, The CVI Range helps guide educational and clinical intervention practices, underscoring the need for and supporting the use of interprofessional, family‑centered collaborative service delivery approaches.”
The study was led by Melinda Y. Chang, M.D., at The Vision Center at Children’s Hospital Los Angeles, in collaboration with researchers from the University of Southern California and the University of Georgia. Co-authors include Dr. Roman-Lantzy and Francesca Crozier-Fitzgerald, M.Ed., CTVI, both practitioners at Pediatric VIEW at The Children’s Home of Pittsburgh.
The research was funded by the NIH/National Eye Institute (K23EY033790), Research to Prevent Blindness, the Knights Templar Eye Foundation, and several private foundations.
Dr. Roman-Lantzy is one of the world’s leading authorities on CVI assessment and intervention. She spent her career pioneering assessment methods and intervention strategies that have changed outcomes for countless children and families. Her work through Pediatric VIEW has positioned The Children’s Home of Pittsburgh as a national leader in pediatric vision assessment and intervention, helping shape best practices across both educational and medical settings.
About The Children's Home of Pittsburgh & Lemieux Family Center
The Children's Home of Pittsburgh, established in 1893, is an independent, nonprofit organization with a mission to promote the health and well-being of infants and children through services that establish and strengthen the family. Programs include Adoption & Permanency Services, Child's Way®, the Pediatric Specialty Hospital, the Pediatric VIEW Program, Therapy Services, and Counseling. The organization also offers free housing for patients and families in its on-site Family Living Center. Learn more at www.childrenshomepgh.org.
###
Ophthalmology Science
Validity and Reliability of the CVI Range for Clinical Research: Baseline and One-Year Results
1-Jul-2026